




**EMORY**  
UNIVERSITY  
SCHOOL OF  
MEDICINE

Department of Psychiatry and Behavioral Sciences

Charles B. Nemeroff, MD, PhD  
*Reunette W. Harris Professor and Chairman*

**MEMORANDUM**

To: Brenda J. Seiton, M.D.  
Assistant Dean for Administration

From: Charles B. Nemeroff, M.D., Ph.D.   
Reunette W. Harris Professor and Chairman

Date: March 19, 2004

Re: Your memorandum of 3/18/04

In the space below, I respond to each of the questions you raised in your memo concerning the additional questions the Conflict of Interest Committee has raised concerning my outside activities and sponsored research.

Generally speaking, the contracts that I forwarded to you call for approximately two weekends per year as for example in the case of the Lilly consultation. Some years the time required for consultation is less and other years, it is more, but in general, it is in the cited ballpark. Therefore, my annual income from any given company for whom I consult varies somewhat depending on their need and my availability. To specifically answer the questions that you raised, in 2002, I received \$16,159.28 from Eli Lilly and in 2003, I received \$6,000. The 2002 figure probably includes some travel reimbursement. It is unclear to me why the committee has repeatedly asked me whether I own any Lilly stock. I do not own any stock in the Eli Lilly company.

In 2002, consultation to Janssen, one of the Johnson & Johnson family of companies, totaled \$38,238.53, though again, this likely includes some travel reimbursement. In 2003, I received a total of \$25,000 in consultation fees from Janssen. Janssen does not issue any stock. It is part of the Johnson & Johnson family, as noted above, and I own 101 shares of J&J stock valued at \$5,983.04 as of January, 2004.

Regarding my relationship with GlaxoSmithKline, I am enclosing a copy of the NIMH Emory GSK U-19 Center Grant (with the 3 funded projects) for the development of novel antidepressants. My responsibilities as Principal Investigator are described in great detail in the grant application. I have no stock options, stock or equity interest in GSK whatsoever. My consultation to GSK is limited to products already on the market and as such, no overlap whatsoever with the content of the U-19 funded grant occurs. Apart from speaking at national symposia, such as the American Psychiatric Association, for which GlaxoSmithKline might

Emory University School of Medicine  
1639 Pierce Drive, Suite 4000, WMB Building  
Atlanta, Georgia 30322

The Robert W. Woodruff Health Sciences Center  
*An equal opportunity, affirmative action university*

Tel   
Fax   
Email @emory.edu

serve as a sponsor, my consultation with this company is limited to chairing their Paroxetine Advisory Board and for that, I am remunerated \$15,000 per year.

I hope I have provided you with all of the information you requested. Please do not hesitate to contact me if additional information is required.

Enclosure